Evidence map›Paper›PMID 30967967›Full record

ArticleRegenerative biomaterials2019

Amyloid fragments and their toxicity on neural cells.

Eva Bystrenova, Zuzana Bednarikova, Marianna Barbalinardo, Cristiano Albonetti, Francesco Valle, Zuzana Gazova

Open access · goldAbstract read
In one paragraph

Article in Regenerative biomaterials, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Eva BystrenovaInstitute of Nanostructured Materials I.S.M.N - C.N.R., via Gobetti, 101, Bologna, Italy.ORCID 0000-0002-4126-7989
Zuzana BednarikovaDepartment of Biophysics, Institute of Experimental Physics SAS, Watsonova 47, Kosice, Slovakia.
Marianna BarbalinardoInstitute of Nanostructured Materials I.S.M.N - C.N.R., via Gobetti, 101, Bologna, Italy.
Cristiano AlbonettiInstitute of Nanostructured Materials I.S.M.N - C.N.R., via Gobetti, 101, Bologna, Italy.
Francesco ValleInstitute of Nanostructured Materials I.S.M.N - C.N.R., via Gobetti, 101, Bologna, Italy.
Zuzana GazovaDepartment of Biophysics, Institute of Experimental Physics SAS, Watsonova 47, Kosice, Slovakia.
Institute of Nanostructured Materials · ITInstitute of Experimental Physics of the Slovak Academy of Sciences · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The formation of amyloid fibrils from soluble proteins is a common form of self-assembly phenomenon that has fundamental connections with biological functions and human diseases. Lysozyme was converted from its soluble native state into highly organized amyloid fibrils. Ultrasonic treatment was used to break amyloid fibrils to fibrillar fragments-seeds. Atomic force microscopy and fluorescence microscopy was employed to characterize the morphology of the amyloid assemblies and neural cells-amyloid complexes. Our results demonstrate that prefibrillar intermediated and their mixture with proteins exhibit toxicity, although native proteins and fibrils appear to have no effect on number of cells. Our findings confirm that innocuous hen lysozyme can be engineered to produce both cytotoxic fibrillar fragments and non-toxic mature amyloid fibrils. Our work further strengthens the claim that amyloid conformation, and not the identity of the protein, is key to cellular toxicity and the underlying specific cell death mechanism.

Indexed as

amyloid fibrilsatomic force microscopyfluorescence microscopyneural cellsprotein aggregation

Identifiers

PMID30967967
PMCPMC6446995
OpenAlexW2922484026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.